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Use of the Metropolis-Hastings Algorithm 
in the Calibration of a Patient Level 
Simulation of Prostate Cancer Screening
Model Structure
A patient level simulation was implemented in Simul8,i 
dynamically linked to Excel ii  whereby the calibration 
process was run using Visual Basic. Figure 1 depicts the 
structure of the disease natural history model.
Key features of the model include:
•	 	Three	progressively	worse	disease	states	from	localised	
disease	(confined	to	prostate)	to	metastatic	disease	
(spread	to	surrounding	organs	and	bones).
•	 	Three	grades	of	disease	aggressiveness	described	
in	terms	of	Gleason	score	(G<7,	G=7,	G>7).
Patients move through the model according to:
•	 If	they	have	prostate	cancer	or	not
•	 Aggressiveness	of	their	prostate	cancer
•	 Sensitivity	of	screening	test
•	 Specificity	of	screening	test
•	 Hazard	of	prostate	cancer	death
•	 Hazard	of	other	cause	death
•	 	Risk	of	clinical	detection;	which	is	assumed	to	
increase with age and stage of prostate cancer.
Figure 1: Model structure and natural history of prostate cancer
 
Data Sources
This	study	utilised	data	from	national	cancer	registries	and	
international	randomised	controlled	trials	(RCTs).	Table	1	lists	
the data and their sources used to calibrate the model.
Table 1: Sources of data used in calibration process
1	 Prostate	Testing	for	Cancer	and	Treatment.
2  Eastern	Cancer	Registry	and	Information	Centre.
3	European	Randomised	Study	of	Screening	for	Prostate	Cancer.
4 Screen detected non-metastatic cancers.
 
Introduction
•	 	Designing	cancer	screening	programmes	
requires an understanding of 
epidemiology, disease natural history 
and screening test characteristics.
•	 	Many	of	these	aspects	of	the	decision	
problem are unobservable and data can 
only tell us about their joint uncertainty.
•	 	A	Metropolis-Hastings	algorithm	
was used to calibrate a patient level 
simulation model of the natural history 
of prostate cancer to national cancer 
registry and international trial data.
•	 	This	method	correctly	represents	
the joint uncertainty amongst the 
model parameters by drawing 
efficiently	from	a	high	dimensional	
correlated parameter space.
•	 	The	calibration	approach	estimates	
the probability of developing prostate 
cancer, the rate of disease progression 
and sensitivity of the screening test.
•	 	This	is	then	used	to	estimate	the	impact	
of prostate cancer screening in the UK.
•	 	This	case	study	demonstrates	that	the	
Bayesian approach to calibration can be 
used to appropriately characterise the 
uncertainty alongside computationally 
expensive simulation models.
Aim of cancer screening:
•	 	Reduce	cancer	mortality,	morbidity	
and treatment costs through early 
diagnosis and intervention.
Challenges:
•	 	Effectiveness	of	different	screening	
programmes unknown.
•	 	Scarce	data	around	disease	process	
due to its unobservable nature.
•	 	Multiple	unknown	parameters	
in cancer screening model.
Solution:
•	 	Develop	loosely	parameterised	
cancer screening simulation model.
•	 	Calibrate	unobservable	model	
parameters to observed data.
•	 	Estimate	impact	of	prostate	cancer	
screening using calibrated model.
Data Source
Age	specific	cancer	incidence UK	Office	of	National	Statistics	(ONS)
Cancer	stage	distributions ProtecT1 RCT 
UK	Cancer	Registry	(ECRIC2)
Gleason	score	(cancer	aggressiveness)	distributions ProtecT1	RCT 
UK	Cancer	Registry	(ECRIC2)
PSA/biopsy test characteristics ERSPC3	RCT	(Rotterdam	section)
Progression Free Survival4 ERSPC3	RCT	(Rotterdam	section)
Overall Survival4 ERSPC3	RCT	(Rotterdam	section)
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Calibration Method
A	Metropolis-Hastings	algorithm	was	used	to	estimate	joint	
posterior probability distributions of model parameters. 
Figure 2 represents the iterative algorithm.
Figure 2: Calibration process
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
•	 	Figure	3	shows	how	the	total	sum	of	squared	errors	
(SSE)	changes	during	the	calibration	process.
•	 	The	total	SSE	quickly	reduces	at	the	start	of	the	
calibration process as the parameter sets converge.
•	 	The	middle	section	depicts	how	the	total	SSE	can	
increase as the algorithm permits sets with a worse 
SSE in order that the complete parameter space is 
explored rather than stopping at a local minimum.
•	 	The	objective	is	for	the	calibration	to	converge	
to a global minimum region.
Figure 3: The total SSE during the calibration process.
Results
•	 	Figure	4	presents	plots	of	the	model	predicted	age	specific	
incidence of prostate cancer and prostate cancer mortality under 
no organised screening against UK national statistics from 2004.
•	 	Model	predicted	age	specific	incidence	and	prostate	
cancer mortality closely matches reported statistics.
Figure 4: Observed and modelled age specific incidence and mortality 
of prostate cancer under no organised screening.
•	 	The	model	was	validated	against	age-	stage	and	Gleason	grade	
data from the British Association of Urological Surgeons 
(BAUS)	Cancer	Registry	for	the	year	2008	(see	Figure	5).
•	 	Model	estimated	age	and	stage	distributions	
correspond well to cancer registry data.
Figure 5: Model predicted age and stage distributions of prostate cancer  
validated against BAUS cancer registry data.
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Conclusion
Parameterising complex conceptual models containing 
unobservable elements is a challenging process.
A	Metropolis-Hastings	algorithm	was	used	to	calibrate	
these unobservable model parameters such that model 
outputs were comparable with observed data.
This	Bayesian	approach	to	calibration	has	wider	
applications than health, and can be used to appropriately 
characterise	uncertainty	in	other	fields	including	within	
computationally expensive simulation models.
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Impact of Screening in the UK
The	cost-effectiveness	of	different	
screening options is currently being 
investigated	on	behalf	of	the	UK	National	
Screening	Committee	using	the	calibrated	
model. Preliminary results suggest that 
single screening strategies have little 
impact	on	overall	age	specific	prostate	
cancer incidence and mortality rates. Any 
overall	survival	benefit	is	likely	to	be	small;	
approximately 1 day for single screening 
strategies and 11 days for repeat screening.
